Business Wire

Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants

Share

Celltrion Group announced today that the company has accelerated development of a nebulised formulation of its neutralising antibody cocktail treatment, to respond to emerging mutants from SARS-CoV-2.

Targeting newly emerging mutations of SARS-CoV-2 and using its already constructed antibody platform, Celltrion has developed a neutralising antibody cocktail consisting of CT-P63 together with its monoclonal antibody treatment Regkirona (regdanvimab, CT-P59), which was recently approved by the European Commission (EC) for the treatment of COVID-19.

Celltrion enrolled 24 healthy volunteers in its global phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of CT-P63 and the company anticipates results by the end of the year.

CT-P63 is a monoclonal antibody targeting SARS-CoV-2 spike receptor binding domain (RBD) as a treatment for COVID-19 infection. Celltrion plans to evaluate neutralisation of new emerging variants tailored to specific regions and assess potential escape mutants by using in vitro pseudo-virus assay. After verifying safety results in phase I clinical trial, Celltrion plans to confirm the extensive neutralising capacity of the cocktail therapy with Regkirona and CT-P63 on new variants as a follow up trial, with a nebulised formulation of Regkirona.

“The mutations in Omicron, also known as B.1.1.529, could help the virus evade the body’s immune response and make it more transmissible” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “Omicron has many mutations in the same regions of the spike protein, however we anticipate CT-P63 to maintain strong neutralising ability against Omicron based on structural analysis by X-ray crystallography and neutralisation data from pseudo-virus testing. By leveraging our antibody platform including Regkirona (CT-P59) and CT-P63, as well as patented formulation, the development of a nebulised cocktail therapy will be accelerated.”

Regkirona has previously demonstrated in vivo efficacy against the most common variants, including the Alpha, Beta, Gamma and Delta variants.

- ENDS -

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About regdanvimab (CT-P59)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre- clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralises the wild type and mutant variants of concern. In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global phase I and phase II/III clinical trials of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild-to-moderate symptoms of COVID-19.1 The EC granted marketing authorisation for Celltrion’s regdanvimab following positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2021.

About nebulised formulation

The nebulised formulation of the monoclonal antibody not only targets SARS-CoV-2 spike receptor binding domain (RBD) and elicit neutralising antibody response but it also has ‘trapping’ mechanism of action and thereby neutralises and traps in mucus with exceptional potency. The muco-trapping antibody platform directly traps the virus in airway mucus, preventing the local spread of the infection, and quickly eliminating the virus from the lungs through the body's natural ability to clear mucus. Nebulised formulation can be readily self-administered by patients, extend critical drug supplies to more patients by reducing the dosage needed, and does not place excessive demands on healthcare staff and infusion clinic space that intravenous (IV) drugs do.

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

1 Celltrion Data on file

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:
Holly Barber
hbarber@hanovercomms.com
+44 (0) 07759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla to Showcase New Pay Station, Mobile and New Solutions at Devcom and Gamescom 202218.8.2022 10:00:00 CEST | Press release

Xsolla, a global video game commerce company, is attending and presenting at Devcom and Gamescom 2022, the world’s largest computer and video games event, from August 22nd to August 28th in Cologne, Germany, EU. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005128/en/ (Graphic: Business Wire) Xsolla is hosting four informative speaking sessions at Devcom on August 22nd and 23rd, including a speaking session from President Chris Hewish. Additionally, Xsolla is exhibiting at Gamescom Hall 2.2, Booth #A-040-B-049, and Devcom booth #B1, where attendees can meet with Xsolla experts and preview the latest products and solutions designed to accelerate video game commerce in 2022. “Having a platform to share Xsolla’s vision with those who are just as passionate about the gaming industry as we are is beyond exciting,” said Chris Hewish, President of Xsolla. “We look forward to speaking with and meeting people from across the g

Bank of Queensland Goes Live on Temenos Banking Cloud18.8.2022 08:30:00 CEST | Press release

Temenos (SIX: TEMN) today announced that Bank of Queensland (BOQ) has gone live with retail banking services on Temenos Banking Cloud for customers served under the BOQ and Virgin Money brands. Work has commenced on the migration of BOQ’s ME brand to Temenos Banking Cloud. Using Temenos cloud-based platform enables BOQ to offer superior customer propositions with personalized offerings at a fraction of the cost of its legacy systems, building a competitive advantage and a low cost-income ratio. Since go live, BOQ has completed over four million transactions on the new platform. The modernization project with Temenos simplifies BOQ’s technology landscape by consolidating 40 systems to a single platform for retail and business banking. As part of the project, BOQ Group will migrate all of its banking operations across three banking brands – leading regional bank BOQ, and challenger banks Virgin Money and ME Bank. BOQ Group is progressively rolling out the Temenos Banking Cloud across the

Altium, IPC Education Foundation, and Arduino Announce Student Electronics Design Competition18.8.2022 07:00:00 CEST | Press release

Altium LLC, the leading printed circuit board (PCB) design software company, is partnering with the IPC Education Foundation (IPCEF) and Arduino to launch the second annual student electronics design challenge. This competition aims to engage, educate, and enhance PCB design capabilities while developing STEM solutions to environmental challenges. The electronics design challenge is an excellent opportunity for students to showcase their talents and gain real-world experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005660/en/ Altium LLC, the IPC Education Foundation, and Arduino are partnering to launch the second annual student electronics design challenge to engage, educate, and enhance students’ proficiencies in PCB design capabilities with a focus on solving some of the world’s most pressing environmental challenges. (Photo: Altium LLC) The Innovation for Environmental Change 2022 International Student Desi

Tavneos ® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)18.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005538/en/ “ANCA-associated vasculitis is a rare, systemic disease which can be rapidly fatal if not appropriately & promptly treated. The variable nature of the disease and its course along with challenging side-effects of current treatment options can severely affect subsequent quality of life for patients,” said John Mills, Vice-Chair of Vasculitis UK. “We very much welcome NICE’

Pre-registration Opens for Hotly Anticipated Racing Game KartRider: Drift18.8.2022 06:01:00 CEST | Press release

Starting today, Nexon’s upcoming party game, KartRider: Drift, is opening pre-registration to racers in preparation for the game’s launch on PC (Steam and Nexon Launcher), Xbox One, PlayStation 4, and mobile (iOS and Android). Kart racer fans who sign up beforehand can receive a special character Model Student Diz when the game officially launches. Additionally, an upcoming cross-platform play test will be announced soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005798/en/ Nexon America KartRider: Drift (Graphic: Nexon) KartRider: Drift boasts multiple game modes and features, delivering exciting racing gameplay regardless of what platform you choose to play. 3 Thrilling Game Modes – Racers can test their grit in “Speed Mode,” a fast-paced mode that will test a racer's reaction skills and strategy using boosts. “Item Mode” offers a wide variety of usable items to attack opposing teams or defend their allies. Fina